INS and Alzheimer disease: As with rifampin, enhancing brain insulin function with intranasal delivery may be a viable approach to ameliorating AD symptoms and attenuating AD-related pathophysiologic processes (149); this is accomplished without perturbation of the peripheral glucose level as little of the intranasal peptide reaches the peripheral circulation (150).